We identified DDX41 mutations in 0.9% of patients with ALL, and the characterize was distinct from myeloid tumors; with a young age of onset, somatic and germline DDX41 variants appeared to be mutually exclusive, the majority (80.0%) of the somatic variants were located on or upstream of the DEAD domain. This evidence concerns the gene DDX41 and myeloid neoplasm.